• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinecarboxylic acids and derivatives

Recent Advances in the Study of N-hydroxypyrimidine-4-carboxamide (CAS: 131346-22-0) in Chemical Biology and Pharmaceutical Research

N-hydroxypyrimidine-4-carboxamide (CAS: 131346-22-0) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have focused on its role as a versatile scaffold in drug discovery, particularly in the development of enzyme inhibitors and modulators of biological pathways. This research brief synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthetic routes, and applications in medicinal chemistry.

A key area of investigation has been the compound's ability to act as a selective inhibitor of metalloenzymes, such as histone deacetylases (HDACs) and matrix metalloproteinases (MMPs). Studies published in the past year demonstrate that N-hydroxypyrimidine-4-carboxamide derivatives exhibit potent inhibitory activity against HDAC isoforms, with promising implications for cancer therapy. The hydroxamic acid moiety in its structure is particularly noteworthy, as it enables chelation of zinc ions in the active sites of these enzymes, thereby blocking their catalytic activity.

Recent synthetic chemistry advancements have expanded the toolbox for creating diverse derivatives of 131346-22-0. A 2023 study in the Journal of Medicinal Chemistry reported an efficient three-step synthesis protocol that improves yield and purity while allowing for extensive structural modifications at the pyrimidine ring. This development has facilitated structure-activity relationship (SAR) studies, leading to the identification of analogs with enhanced pharmacokinetic properties and target specificity.

In the realm of drug discovery, computational modeling studies have provided valuable insights into the binding modes of N-hydroxypyrimidine-4-carboxamide derivatives with their biological targets. Molecular dynamics simulations have revealed that subtle modifications to the carboxamide group can significantly influence binding affinity and selectivity. These findings are guiding the rational design of next-generation inhibitors with improved therapeutic profiles.

Emerging preclinical data suggest potential applications beyond oncology. Recent investigations have explored the compound's anti-inflammatory properties through its modulation of NF-κB signaling pathways. Additionally, its ability to cross the blood-brain barrier has sparked interest in neurological disorders, with preliminary studies showing neuroprotective effects in models of neurodegenerative diseases.

The pharmaceutical industry has taken notice of these developments, with several companies filing patents for novel N-hydroxypyrimidine-4-carboxamide derivatives in 2022-2023. These patents cover compositions ranging from standalone therapeutic agents to combination therapies with existing drugs, reflecting the compound's versatility in treatment strategies.

While the research landscape is promising, challenges remain in optimizing the pharmacological properties of 131346-22-0 derivatives. Current efforts focus on addressing issues related to metabolic stability and off-target effects. The development of prodrug strategies and targeted delivery systems represents an active area of investigation that may overcome these limitations.

In conclusion, N-hydroxypyrimidine-4-carboxamide (131346-22-0) continues to demonstrate significant potential in chemical biology and drug discovery. The convergence of synthetic chemistry, computational modeling, and biological evaluation is driving the development of novel therapeutic agents based on this scaffold. As research progresses, this compound class may yield important clinical candidates for multiple disease indications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)